Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Six Patent Applications Related to RNAi: Apr 24, 2008

Premium
Title: RNAi Modulation of MLL-AF4 and Uses Thereof
 
Number: 7,361,752
 
Filed: Dec. 14, 2005
 
Lead Inventor: Olaf Heidenreich, Alnylam Pharmaceuticals
 
The invention, the patent’s abstract states, relates to “compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the down-regulation of MLL-AF4 by chemically modified oligonucleotides.”
 

 
Title: Compositions and Methods for Inhibiting or Inducing Adipogenesis
 
Number: 20080090257
 
Filed: Oct. 11, 2007
 
Inventor: Dechun Li, St. Louis University
 
“This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells,” the patent application’s abstract states. “Specifically, the invention is directed to compositions which regulate transcription factor PPAR gamma and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis.”
 
The patent application also claims “an interfering RNA that may be used to inhibit adipogenesis,” the abstract notes.
 

 
Title: siRNA Targeting Complement Component 3
 
Number: 20080090997
 
Filed: Oct. 26, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for C3.”
 

 
Title: Functional and Hyperfunctional siRNA Directed Against Bcl-2
 
Number: 20080091001, 20080091002, 20080091003, 20080091004
 
Filed: Oct. 15-18, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent applications’ abstracts state. “By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing Bcl-2.”

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.